drugset / Trial / NCT01668524

ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects

NCT01668524

Phase 2 Completed 12 enrolled Altheos, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This single-site, dose-escalation study will evaluate safety and tolerability of increasing concentrations of ATS907 in 12 subjects with Primary Open Angle Glaucoma and/or Ocular Hypertension

Timeline

Start
2012-08
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ATS907 Unknown